Government Tells High Court Not To Review Drug Trademark Dispute

(February 2, 2017, 2:52 PM EST) -- WASHINGTON, D.C. — The federal government argues in a Jan. 24 opposition brief that the U.S. Supreme Court should not review a ruling that held Bayer Consumer Care AG (BCC) and...
To view the full article, register now.